OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
11
Results
Show all
Save search
Copy query
Show results for
Unknown
(11)
Publication Date
Release Date
2025
(3)
2024
(2)
2021
(2)
2026
(1)
2023
(1)
2022
(1)
2020
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Not available
S-EPMC8892808
|
biostudies-literature
Cite
Molecular detection of SARS-CoV-2 from indoor air samples in environmental monitoring needs adequate temporal coverage and infectivity assessment.
Not available
S-EPMC8065246
|
biostudies-literature
Cite
Hematochemical hallmarks as markers of pulmonary TB severity: A multicenter cross-sectional study.
Not available
S-EPMC11999573
|
biostudies-literature
Cite
Paper-based electrochemical device for early detection of integrin αvβ6 expressing tumors.
Not available
S-EPMC10957923
|
biostudies-literature
Cite
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Not available
S-EPMC10024144
|
biostudies-literature
Cite
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Not available
S-EPMC8314140
|
biostudies-literature
Cite
Baseline Association between Healthy Eating Index-2015 and Health-Related Quality of Life in Breast Cancer Patients Enrolled in a Randomized Trial.
Not available
S-EPMC11274909
|
biostudies-literature
Cite
Vitamin D Supplementation and Testosterone Levels in Breast Cancer Survivors.
Not available
S-EPMC12564732
|
biostudies-literature
Cite
Lacosamide is Associated with a Higher Treatment Persistence at 12 Months than Brivaracetam and Perampanel Despite Similar Efficacy.
Not available
S-EPMC12804576
|
biostudies-literature
Cite
Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study.
Not available
S-EPMC12291020
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets